1150 related articles for article (PubMed ID: 15706429)
21. Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder.
Kibar Y; Goktas S; Kilic S; Yaman H; Onguru O; Peker AF
Ann Clin Lab Sci; 2006; 36(1):31-8. PubMed ID: 16501234
[TBL] [Abstract][Full Text] [Related]
22. [Molecular markers for transitional cell carcinoma of bladder].
Kleinmann J; Siegel YI; Zisman A
Harefuah; 2003 Jul; 142(7):531-5, 565. PubMed ID: 12908389
[TBL] [Abstract][Full Text] [Related]
23. Noninvasive detection of bladder cancer with the BTA stat test.
Pode D; Shapiro A; Wald M; Nativ O; Laufer M; Kaver I
J Urol; 1999 Feb; 161(2):443-6. PubMed ID: 9915422
[TBL] [Abstract][Full Text] [Related]
24. Urinary level of nuclear matrix protein 22 in the diagnosis of bladder cancer: experience with 130 patients with biopsy confirmed tumor.
Casella R; Huber P; Blöchlinger A; Stoffel F; Dalquen P; Gasser TC; Lehmann K
J Urol; 2000 Dec; 164(6):1926-8. PubMed ID: 11061883
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma.
Nisman B; Barak V; Shapiro A; Golijanin D; Peretz T; Pode D
Cancer; 2002 Jun; 94(11):2914-22. PubMed ID: 12115379
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the telomeric repeat amplification protocol (TRAP) assay for telomerase as a diagnostic modality in recurrent bladder cancer.
Dalbagni G; Han W; Zhang ZF; Cordon-Cardo C; Saigo P; Fair WR; Herr H; Kim N; Moore MA
Clin Cancer Res; 1997 Sep; 3(9):1593-8. PubMed ID: 9815848
[TBL] [Abstract][Full Text] [Related]
27. Detection of loss of heterozygosity in the p53 tumor-suppressor gene with PCR in the urine of patients with bladder cancer.
Friedrich MG; Erbersdobler A; Schwaibold H; Conrad S; Huland E; Huland H
J Urol; 2000 Mar; 163(3):1039-42. PubMed ID: 10688045
[TBL] [Abstract][Full Text] [Related]
28. [Clinical value of combined detection with urinary bladder cancer antigen, hyaluronic acid and cytokeratin 20 in diagnosis of bladder cancer].
Pu XY; Wang ZP; Chen YR; Wu YL; Wang HP; Wang XH
Ai Zheng; 2008 Sep; 27(9):970-3. PubMed ID: 18799038
[TBL] [Abstract][Full Text] [Related]
29. Microsatellite instability as prognostic marker in bladder tumors: a clinical significance.
Vaish M; Mandhani A; Mittal RD; Mittal B
BMC Urol; 2005 Jan; 5():2. PubMed ID: 15647110
[TBL] [Abstract][Full Text] [Related]
30. Prospective evaluation of genetic abnormalities and telomerase expression in exfoliated urinary cells for bladder cancer detection.
Neves M; Ciofu C; Larousserie F; Fleury J; Sibony M; Flahault A; Soubrier F; Gattegno B
J Urol; 2002 Mar; 167(3):1276-81. PubMed ID: 11832713
[TBL] [Abstract][Full Text] [Related]
31. Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma.
Klein A; Zemer R; Buchumensky V; Klaper R; Nissenkorn I
Cancer; 1998 Jan; 82(2):349-54. PubMed ID: 9445193
[TBL] [Abstract][Full Text] [Related]
32. [Usefulness of BTA Stat test (Bard) in the diagnosis of bladder cancer. Preliminary results and comparison with cytology and cystoscopy].
Gutiérrez Baños JL; Martín García B; Hernández Rodríguez R; Portillo Martín JA; Correas Gómez MA; del Valle Schaan JI; Roca Edreira A; Villanueva Peña A; Gutíerrez García R; De Diego Rodríguez E; Rado Velázquez MA
Arch Esp Urol; 1998 Oct; 51(8):778-82. PubMed ID: 9859583
[TBL] [Abstract][Full Text] [Related]
33. Immunostaining of cytokeratin 20 in cells from voided urine for detection of bladder cancer.
Golijanin D; Shapiro A; Pode D
J Urol; 2000 Dec; 164(6):1922-5. PubMed ID: 11061882
[TBL] [Abstract][Full Text] [Related]
34. Routine follow-up cystoscopy in detection of recurrence in patients being monitored for bladder cancer.
Raitanen MP; Leppilahti M; Tuhkanen K; Forssel T; Nylund P; Tammela T;
Ann Chir Gynaecol; 2001; 90(4):261-5. PubMed ID: 11820414
[TBL] [Abstract][Full Text] [Related]
35. Should bladder biopsies be performed routinely after bacillus Calmette-Guérin treatment for high-risk superficial transitional cell cancer of the bladder?
Guy L; Savareux L; Molinié V; Botto H; Boiteux JP; Lebret T
Eur Urol; 2006 Sep; 50(3):516-20; discussion 520. PubMed ID: 16632184
[TBL] [Abstract][Full Text] [Related]
36. [Microsatellite instability in urine sediments from patients with transitional cell carcinoma of bladder and its clinical value].
Lü Y; Tang D; Yu L; Ding Y; Liu L; Guo Y
Zhonghua Wai Ke Za Zhi; 2000 Apr; 38(4):294-6. PubMed ID: 12828175
[TBL] [Abstract][Full Text] [Related]
37. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence.
Boman H; Hedelin H; Holmäng S
J Urol; 2002 Jan; 167(1):80-3. PubMed ID: 11743280
[TBL] [Abstract][Full Text] [Related]
38. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine.
Halling KC; King W; Sokolova IA; Karnes RJ; Meyer RG; Powell EL; Sebo TJ; Cheville JC; Clayton AC; Krajnik KL; Ebert TA; Nelson RE; Burkhardt HM; Ramakumar S; Stewart CS; Pankratz VS; Lieber MM; Blute ML; Zincke H; Seelig SA; Jenkins RB; O'Kane DJ
J Urol; 2002 May; 167(5):2001-6. PubMed ID: 11956427
[TBL] [Abstract][Full Text] [Related]
39. Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guerin and mitomycin C on urinary survivin levels and outcome.
Hausladen DA; Wheeler MA; Altieri DC; Colberg JW; Weiss RM
J Urol; 2003 Jul; 170(1):230-4. PubMed ID: 12796695
[TBL] [Abstract][Full Text] [Related]
40. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors.
Giannopoulos A; Manousakas T; Gounari A; Constantinides C; Choremi-Papadopoulou H; Dimopoulos C
J Urol; 2001 Aug; 166(2):470-5. PubMed ID: 11458049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
